Dr. Jennifer Litton, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Massachusetts / Boston Campus

  Medical School, 2000

• Cancers Associated withBRCA1 andBRCA2 Mutations other than Breast and Ovarian, 2014-09-15

• Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naive gBRCA+ breast cancers, 2022-05-10

• Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a GermlineBRCA1/2Mutation, 2021-10-03

• Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer, 2022-03-04

• Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy, 2012-05-23

• Early Ultrasound Evaluation Identifies Excellent Responders to Neoadjuvant Systemic Therapy in Patients with Triple Negative Breast Cancer, 2021-04-20

• Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal CarcinomaIn situWho Underwent Clinical BRCA Genetic Testing, 2016-04-27

• Phase Ib Trial of Folate Binding Protein (FBP)-Derived Peptide Vaccines, E39 and an Attenuated Version, E39': An Analysis of Safety and immune Response, 2018-03-21

• Breast radiotherapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing, 2021-09-25

• Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations, 2011-08-10

• High Incidence of Germline BRCA Mutation in Patients with ER low positive/PR low positive/HER-2 neu negative Tumors, 2015-08-17

• Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer, 2021-10-01

• Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer, 2017-11-27

• Earlier Age of Onset ofBRCAMutation-Related Cancers in Subsequent Generations, 2011-09-12

• Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass, 2012-03-04

• PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens, 2023-08-02

• Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer, 2018-05-07

• Predictors that influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ who were evaluated forBRCAgenetic testing, 2014-05-06

• Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer, 2023-10-02

• Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditaryBRCAmutation, 2022-09-01

• Clinical outcomes based on multigene profiling in metastatic breast cancer patients, 2016-10-28

• Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancer, 2021-07-26

• Outcomes of children exposedin uteroto chemotherapy for breast cancer, 2014-12-30

• Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC), 2020-09-13

• Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer, 2022-07-01

• Young Onset HER2 Positive Breast Cancer is Associated with GermlineTP53Mutations, 2011-07-14

• Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes, 2017-10-31

• A Population of Heterogeneous Breast Cancer Patient Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild Type Tumors, 2017-11-01

• Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial, 2015-02-06

• BRCAMutations in Women with Inflammatory Breast Cancer, 2017-10-17

• Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype, 2011-07-20

• Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer, 2012-02-22

• Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence, 2016-08-31

• Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer, 2016-06-10

• Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients., 2020-02-18

• Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI, 2023-02-06

• Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?, 2015-05-07

• PD-L1 Expression in Triple Negative Breast Cancer, 2014-01-10

• Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients, 2017-03-17

• Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial, 2023-06-21

• Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer, 2015-03-24

• Characterization of bone only metastasis patients with respect to tumor subtypes, 2018-01-25

• MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer, 2022-08-01

• A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer, 2021-11-15

• Breast cancer diagnosis during pregnancy, 2009-05-28

• Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI, 2023-01-20

• Metformin promotes antitumor immunity via endoplasmic reticulum-associated degradation of PD-L1, 2018-08-16

• Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence, 2020-04-22

• Breast Cancer in Adolescents and Young Adults, 2018-08-28